Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc.

ABOS·NASDAQ

$2.37

+2.6%
HealthcareBiotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

At a Glance

Live Snapshot
Market Cap$143.26M
EPS-2.0000
P/E Ratio-1.18
Earnings Date08/11/2026

abos

Cost of Revenue

Last Annual Value

184.00K

3-Year CAGR

%

5-Year CAGR

-53%

10-Year CAGR

36%

Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Competitors Analysis of Cost of Revenue

ABOS · NASDAQ
CompanyCost of Revenue
CAGR 3Y
CAGR 5Y
CAGR 10Y
184.00K
N/A-56.9%N/A 
SEER logo
Seer, Inc.
NASDAQ:SEER
8.11M
-16.1%3.7%N/A
0.00
N/AN/AN/A
7.97M
1.0%N/AN/A
PEPG logo
PepGen Inc.
NASDAQ:PEPG
1.40M
5.7%N/AN/A
534.00K
N/AN/AN/A
403.58K
2.2%N/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
11.02M
-64.1%-42.9%-19.4%
0.00
N/AN/AN/A
ALEC logo
Alector, Inc.
NASDAQ:ALEC
9.66M
3.0%-44.9%-3.4%
0.00
N/AN/AN/A
Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. Fair Value Envelope

ABOS · NASDAQ

Our analysis suggests that ABOS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.365, this represents a potential HIDDEN relative to our calculated worth for Acumen Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $2.365